Paris/France—January 8, 2021: Biomillenia and Amyris, Inc., a leading synthetic biotechnology company in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty, and Flavors & Fragrances markets, announced today the signing of a R&D collaboration agreement aiming to evaluate Biomillenia’s microfluidics-based culture platform for phenotypic screening of Amyris’s engineered production strains. Biomillenia will contribute its …
BASF and Biomillenia join forces in microbiome research to promote healthy skin
Paris/France – October 7, 2019 – BASF and Biomillenia today announced the signing of a microbiome discovery agreement. The collaboration aims to identify novel dermocosmetic active ingredients involved in promoting skin health. The French company Biomillenia will contribute its unique microbiome-on-a-chip technology that has the ability to grow specific microbes and maintain a higher diversity of living microbes than with …
Microbiome-based skincare product concepts are awarded with the Innov’up Leader PIA grant
Biomillenia’s innovative skincare product development pipeline was rewarded with the maximum amount of non-dilutive funding from the Innov’up Leader PIA program by BPIFrance Financement. We are proud to have been selected as a winner of this product development grant that will support the creation of novel skincare solutions that act through modulation of the microbiota of the human skin and …
Biomillenia Leverages QIAGEN Bioinformatics in Microbiome-on-a-Chip Discovery of Unculturable Microbes
Collaboration data presented at 3rd Annual European Microbiome Congress Microbiome-on-a-chip technology capable of culturing, screening and isolating bacteria in single step while demonstrating targeted benefits QIAGEN’s Microbial Genomics Pro Suite enables analysis of microbial sequences and microbiomes Paris, France, and London, UK, November 28, 2017—Biomillenia, the developer of Smart Microbes™, announced today a collaboration with QIAGEN N.V. (NASDAQ: QGEN, Frankfurt …
BIOMILLENIA collaborates with MERCK on BIOevolution project
Paris, France, October 4, 2016—BIOMILLENIA announces its collaboration with the life science business of Merck on the development of an improved enzyme used in vaccine production processes. Following a successful technology evaluation project employing BIOMILLENIA’s proprietary droplet-based microfluidic cell culture and screening technology platform, BIOMILLENIA and Merck will collaborate on the development of a market-leading enzyme in Merck’s portfolio of …
BIOMILLENIA partners with SOUFFLET on BIOprospect co-development of cellulolytic and proteolytic enzymes
Paris, France, December 1st, 2015—BIOMILLENIA SAS announces to partner with SOUFFLET BIOTECHNOLOGIES, a division of the french leading agricultural company SOUFFLET on co-developing novel enzymes within a BIOprospect project framework. BIOMILLENIA’s BIOprospect offering creates novel industry solutions for the manufacturing of biology-based products by exploring new enzymes and microbes from natural samples at unprecedented throughput. Ultrasensitive detection of enzyme activities …